Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AstraZeneca
Pathos AI, Inc.
Cedars-Sinai Medical Center
K36 Therapeutics, Inc.
Atavistik Bio, Inc
Inhibrx Biosciences, Inc
Cancer Research UK
NiKang Therapeutics, Inc.
University of Washington
The Netherlands Cancer Institute
Marengo Therapeutics, Inc.
Novartis
Advanced Accelerator Applications
Revolution Medicines, Inc.
Endocyte
Stanford University
UroGen Pharma Ltd.
Poseida Therapeutics, Inc.
VA Greater Los Angeles Healthcare System
University Health Network, Toronto
University Medical Center Groningen
Promontory Therapeutics Inc.
Steba Biotech S.A.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Aragon Pharmaceuticals, Inc.
Hoffmann-La Roche
Revolution Medicines, Inc.
Region Skane
Revolution Medicines, Inc.
Seoul National University Bundang Hospital
Advanced Accelerator Applications
Steba Biotech S.A.
University Hospital, Bordeaux
Steba Biotech S.A.
University of Oulu
Endo Pharmaceuticals
Bioniche Life Sciences Inc.
Dendreon
Life Molecular Imaging SA
Steba Biotech S.A.
Steba Biotech S.A.
UroGen Pharma Ltd.
Arno Therapeutics
Steba Biotech S.A.
Medical Enterprises Europe B.V.
Medical Enterprises Europe B.V.